Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012, Article ID 897178, 7 pages
http://dx.doi.org/10.1100/2012/897178
Clinical Study

Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients

1State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, China
2Department of Radiation Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, China
3Department of Medical Oncology, The First affiliated Hospital of Sun Yat-sen University, 58 zhongshan Road, Guangzhou 510080, China
4Departments of Oncology, Kiang Wu Hospital, Kiang Wu Road, Macau, China
5Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, China
6Department of Pathology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, China

Received 7 July 2012; Accepted 19 September 2012

Academic Editors: A. Bettaieb, T. Robak, and X. Thomas

Copyright © 2012 Ying Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. O. Armitage, “A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma,” Blood, vol. 89, no. 11, pp. 3909–3918, 1997. View at Google Scholar · View at Scopus
  2. A. A. Alizadeh, M. B. Elsen, R. E. Davis et al., “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling,” Nature, vol. 403, no. 6769, pp. 503–511, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. C. P. Hans, D. D. Weisenburger, T. C. Greiner et al., “Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray,” Blood, vol. 103, no. 1, pp. 275–282, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Rosenwald, G. Wright, W. C. Chan et al., “The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma,” The New England Journal of Medicine, vol. 346, no. 25, pp. 1937–1947, 2002. View at Publisher · View at Google Scholar
  5. W. H. Wilson, S.-H. Jung, P. Porcu et al., “A cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype,” Haematologica, vol. 97, no. 5, pp. 758–765, 2012. View at Publisher · View at Google Scholar
  6. K. Gu, D. D. Weisenburger, K. Fu et al., “Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation,” Hematological Oncology, vol. 30, no. 3, pp. 143–149, 2012. View at Publisher · View at Google Scholar
  7. P. L. Zinzani, A. Broccoli, V. Stefoni et al., “Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients,” Cancer, vol. 116, no. 24, pp. 5667–5675, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. J. Ninan, P. D. Wadhwa, and P. Gupta, “Prognostication of diffuse large B-cell lymphoma in the rituximab era,” Leukemia and Lymphoma, vol. 52, no. 3, pp. 360–373, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. L. H. Sehn, B. Berry, M. Chhanabhai et al., “The revised international prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP,” Blood, vol. 109, no. 5, pp. 1857–1861, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Lenz, G. Wright, S. S. Dave et al., “Stromal gene signatures in large-B-cell lymphomas,” New England Journal of Medicine, vol. 359, no. 22, pp. 2313–2323, 2008. View at Publisher · View at Google Scholar
  11. W. W. L. Choi, D. D. Weisenburger, T. C. Greiner et al., “A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy,” Clinical Cancer Research, vol. 15, no. 17, pp. 5494–5502, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Feugier, A. Van Hoof, C. Sebban et al., “Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the groupe d'etude des lymphomes de l'adulte,” Journal of Clinical Oncology, vol. 23, no. 18, pp. 4117–4126, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. W. H. Wilson, K. Dunleavy, S. Pittaluga et al., “Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers,” Journal of Clinical Oncology, vol. 26, no. 16, pp. 2717–2724, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Nyman, M. Adde, M. L. Karjalainen-Lindsberg et al., “Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy,” Blood, vol. 109, no. 11, pp. 4930–4935, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Seki, K. Ohshima, T. Fujisaki et al., “Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era,” Cancer Science, vol. 100, no. 10, pp. 1842–1847, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. M. S. Czuczman, A. J. Grillo-López, B. Alkuzweny, R. Weaver, A. Larocca, and P. Mclaughlin, “Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab,” Leukemia and Lymphoma, vol. 47, no. 9, pp. 1830–1840, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Koivula, E. Valo, A. Raunio, S. Hautaniemi, and S. Leppä, “Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma,” Oncology Reports, vol. 25, no. 4, pp. 1183–1190, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. R. E. Davis, K. D. Brown, U. Siebenlist, and L. M. Staudt, “Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells,” Journal of Experimental Medicine, vol. 194, no. 12, pp. 1861–1874, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. L. T. Lam, R. E. Davis, V. N. Ngo et al., “Compensatory IKKα activation of classical NF-κB signaling during IKKβ inhibition identified by an RNA interference sensitization screen,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 52, pp. 20798–20803, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Yeung, P. Janosch, B. McFerran et al., “Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the Raf kinase inhibitor protein,” Molecular and Cellular Biology, vol. 20, no. 9, pp. 3079–3085, 2000. View at Publisher · View at Google Scholar · View at Scopus